InflaRx Balance Sheet Health
Financial Health criteria checks 4/6
InflaRx has a total shareholder equity of €102.6M and total debt of €0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are €120.2M and €17.6M respectively.
Key information
0%
Debt to equity ratio
€0
Debt
| Interest coverage ratio | n/a |
| Cash | €12.77m |
| Equity | €102.58m |
| Total liabilities | €17.63m |
| Total assets | €120.21m |
Recent financial health updates
We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Dec 23
InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 17We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Mar 28Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?
Nov 30Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation
Jul 16Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
Apr 01Recent updates
We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Dec 23InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 17We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Mar 28Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?
Nov 30InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients
Sep 29InflaRx reports Q2 results
Aug 05InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients
Jul 26Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation
Jul 16InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder
Jul 06InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy
Jun 29Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
Apr 01Our First Look At InflaRx
Dec 29Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)
Dec 15InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 27InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks
Aug 25InflaRx initiates mid-stage vilobelimab skin cancer trial
Jun 08We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth
May 01Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?
Mar 02We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Jan 08
InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder
Jan 05InflaRx reports Q3 results
Oct 29Financial Position Analysis
Short Term Liabilities: IFRX's short term assets (€109.5M) exceed its short term liabilities (€16.8M).
Long Term Liabilities: IFRX's short term assets (€109.5M) exceed its long term liabilities (€782.6K).
Debt to Equity History and Analysis
Debt Level: IFRX is debt free.
Reducing Debt: IFRX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IFRX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IFRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.2% each year